BR112019003951A2 - métodos e composição para a predição da atividade de enzastaurina - Google Patents
métodos e composição para a predição da atividade de enzastaurinaInfo
- Publication number
- BR112019003951A2 BR112019003951A2 BR112019003951A BR112019003951A BR112019003951A2 BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2 BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2
- Authority
- BR
- Brazil
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção descreve biomarcadores que foram descobertos para correlacionar com respostas individuais variadas (por exemplo, eficácia, efeito adverso e outros pontos finais) à enzastaurina, no tratamento de doenças tais como, dlbcl, gbm e outros tipos de câncer. os biomarcadores recentemente descritos e outros em desequilíbrio de ligação com eles podem ser usados em testes de diagnóstico complementares que podem ajudar a prever respostas de fármacos e aplicar os fármacos apenas àqueles que serão beneficiados, ou excluir aqueles que podem não ser benéficos, pelo tratamento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003951A2 true BR112019003951A2 (pt) | 2019-06-25 |
Family
ID=59923555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003951A BR112019003951A2 (pt) | 2016-09-01 | 2017-08-31 | métodos e composição para a predição da atividade de enzastaurina |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (pt) |
| EP (1) | EP3507384B1 (pt) |
| JP (3) | JP7197915B2 (pt) |
| KR (1) | KR20190046935A (pt) |
| CN (1) | CN109952383B (pt) |
| AU (1) | AU2017318669B2 (pt) |
| BR (1) | BR112019003951A2 (pt) |
| CA (1) | CA3035386A1 (pt) |
| JO (1) | JOP20190025A1 (pt) |
| MX (1) | MX2019002377A (pt) |
| PH (1) | PH12019500422A1 (pt) |
| RU (1) | RU2019109011A (pt) |
| SG (2) | SG11201901762WA (pt) |
| TW (2) | TWI771317B (pt) |
| WO (1) | WO2018045240A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| WO2020055698A1 (en) * | 2018-09-12 | 2020-03-19 | Denovo Biopharma Llc | Combination of enzastaurin and inhibitors of btk and uses thereof |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| US20240321421A1 (en) * | 2021-07-23 | 2024-09-26 | Kaohsiung Medical University | Clinical therapeutic drug prediction and recommendation system and method for evaluating efficacy of second-generation hormone drug in treatment of prostate cancer |
| CN118339312A (zh) * | 2021-11-23 | 2024-07-12 | 索元生物医药(美国)有限公司 | 用于评估多核苷酸递送和癌疗法之功效的组合物和方法 |
| US20230185457A1 (en) * | 2021-12-13 | 2023-06-15 | Google Llc | Optimizing Data Placement Based on Data Temperature and Lifetime Prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0817627T3 (da) | 1993-12-23 | 2005-06-06 | Lilly Co Eli | Inhibitorer af proteinkinase C |
| WO2002014500A2 (en) * | 2000-08-16 | 2002-02-21 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2012106267A1 (en) | 2011-01-31 | 2012-08-09 | Wen Luo | Method for discovering pharmacogenomic biomarkers |
| KR20140039278A (ko) * | 2011-06-08 | 2014-04-01 | 드노보 바이오파마 (항주) 리미티드 코포레이션 | 레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물 |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en active Active
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Application Discontinuation
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en active Application Filing
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh active
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019109011A3 (pt) | 2021-01-22 |
| RU2019109011A (ru) | 2020-10-05 |
| AU2017318669B2 (en) | 2023-04-20 |
| CN109952383A (zh) | 2019-06-28 |
| MX2019002377A (es) | 2019-09-05 |
| TW201812125A (zh) | 2018-04-01 |
| JP7197915B2 (ja) | 2022-12-28 |
| KR20190046935A (ko) | 2019-05-07 |
| TWI771317B (zh) | 2022-07-21 |
| SG10201912134TA (en) | 2020-02-27 |
| TW202313973A (zh) | 2023-04-01 |
| US11421280B2 (en) | 2022-08-23 |
| CN109952383B (zh) | 2024-01-05 |
| JP2022173308A (ja) | 2022-11-18 |
| SG11201901762WA (en) | 2019-03-28 |
| AU2017318669A1 (en) | 2019-03-07 |
| JP2020188816A (ja) | 2020-11-26 |
| JP2019528705A (ja) | 2019-10-17 |
| JOP20190025A1 (ar) | 2019-02-19 |
| CA3035386A1 (en) | 2018-03-08 |
| US20190233902A1 (en) | 2019-08-01 |
| US20230074781A1 (en) | 2023-03-09 |
| PH12019500422A1 (en) | 2019-05-27 |
| WO2018045240A1 (en) | 2018-03-08 |
| EP3507384B1 (en) | 2023-08-30 |
| EP3507384A1 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003951A2 (pt) | métodos e composição para a predição da atividade de enzastaurina | |
| BR112017028353A2 (pt) | anticorpos para cd40 com atividade agonista melhorada | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112017026467A2 (pt) | uso de exossomos para o tratamento de doença | |
| BR112017002342A2 (pt) | novos anticorpos e usos dos mesmos | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
| BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
| BR112018013853A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer | |
| BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| CL2019002427A1 (es) | Inhibición de smarca2 para el tratamiento de cáncer. | |
| SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
| BR112017008045A2 (pt) | compostos como inibidores de nik | |
| BR112016029334A2 (pt) | produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos | |
| PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
| BR112017007715A2 (pt) | derivados de tienopirimidina como inibidores de nik | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |